(Updates with Italy's deal with Pfizer, Egypt's deal with Merck and EU's Pfizer approval) Jan 28 (Reuters) - Countries are scrambling to buy the antiviral pills developed by Merck and Pfizer for adult COVID-19 patients. The European Medicines Agency on Jan. 27 gave the green light to use Pfizer's antiviral COVID-19 pill for treating adults at risk of severe illness. The regulator expects to give a final ruling on Merck's molnupiravir by the end of February. On Friday, India's Dr.Reddy's Labs said it had started commercial production of a generic version of Merck's treatment. Egypt, which approved Merck's COVID pill on Jan. 25, said the drug will be produced locally. Here is an alphabetical list of other countries and their orders: Merck pill COUNTRY VOLUME PRICE TIMING OF SOURCE DELIVERY Africa Australia 300,000 doses Belgium 10,000 courses Canada 500,000 courses Egypt to be produced locally EU Germany 80,000 doses Indonesia 600,000 - 1 December million doses 2021 , Ireland Italy 40,000 doses 40,000 + 12,000 doses in already week 3 distributed 2022 Japan 1.6 mln $1.2 courses billion Malaysia 150,000 courses Philippines 300,000 100-150 November courses pesos 2021 ($1.97-$2 .96) per pill Singapore South Korea 200,000 courses Switzerland 8,640 doses Jan 2022 "at the latest" Thailand 200,000 courses UK 2,230,000 early courses 2022 United 3,100,000 $700 per States courses course, total of $2.2 billion Pfizer pill COUNTRY VOLUME PRICE TIMING OF SOURCE DELIVERY Africa Australia 500,000 https://bit.ly/3BTUQeL courses Belgium 10,000 courses Canada 1,000,000 30,400 doses courses already received, 120,000 to be delivered by end-March EU Germany Ireland Israel 100,000 Italy 600,000 during [n complete 2022, with L8N2TP0AJ] courses first bit.ly/3g1w6Jj 11,200 courses to be delivered in the first week of February South Korea 70,000 courses Thailand UK 2,750,000 Early 2022 courses United 20,000,000 $530 per Expects 4 States courses course, mln courses $5.29 by end-Jan, billion 10 mln by for the June first 10 mln courses ordered ($1 = 85.4800 taka) (Reporting by Ina Kreutz, Agnieszka Gosciak and Federica Urso; Editing by Milla Nissi and Philippa Fletcher)
Our Standards: The Thomson Reuters Trust Principles.
